CSTF2-mediated 3'UTR shortening drives oncogenic activation of GPC3 in hepatocellular carcinoma

Soyoung Jeon1,2,3, Eunbi Shin1,2,3, Jin Woong Ha1,2,3

  • 1Department of Pathology, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, 06591, Seoul, Republic of Korea.

Oncogene
|August 10, 2026
PubMed

Insights

Alternative polyadenylation shortens 3' untranslated regions (3'UTRs) in hepatocellular carcinoma (HCC), activating oncogenes like Glypican-3 (GPC3). This study reveals the CSTF2-GPC3 axis drives HCC progression.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genomics

Background:

  • Alternative polyadenylation (APA) generates mRNA variants affecting gene expression.
  • 3'UTR shortening in cancer can lead to oncogene activation by evading microRNA repression.
  • The role of APA in hepatocellular carcinoma (HCC) is not well understood.

Purpose of the Study:

  • To investigate mRNA length alterations in human HCC.
  • To identify APA regulators and their targets in HCC.
  • To elucidate the functional consequences of 3'UTR shortening in HCC.

Main Methods:

  • Profiling of mRNA length alterations in human HCC transcriptome datasets.
  • Analysis of Glypican-3 (GPC3) expression and its association with prognosis.
  • Investigating the role of Cleavage Stimulation Factor 2 (CSTF2) in APA and GPC3 regulation.
  • Functional studies involving gene knockdown and overexpression.

Main Results:

  • ~77% of altered mRNAs showed 3'UTR shortening in HCC.
  • GPC3 was the most prominent shortened transcript, linked to poor prognosis.
  • CSTF2 upregulation correlated with GPC3 expression and predicted adverse outcomes.
  • CSTF2 modulated GPC3 3'UTR length, enhancing GPC3 protein expression and promoting HCC cell growth.
  • GPC3 3'UTR shortening relieved repression by miR-96-5p and miR-140-5p.

Conclusions:

  • CSTF2-driven APA activates oncogenic GPC3 in HCC.
  • The CSTF2-GPC3 axis is a key mechanism in HCC progression.
  • This axis represents a potential therapeutic target for HCC.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...